Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780507 | 0.87 | CYP19A1 (0.54) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL24665771 | 0.81 | CYP19A1 (0.60) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL29055930 | 0.81 | CYP19A1 (0.60) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL23861821 | 0.81 | CYP19A1 (0.65) | CYP19A1NPC1RAB9AHSP90AB1HRH4 | |
| SCHEMBL305197 | 0.80 | CYP19A1 (0.49) | CYP19A1HDAC1HSP90AB1ALDH1A1LMNA | |
| SCHEMBL28676360 | 0.79 | CYP19A1 (0.66) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL2494737 | 0.79 | NOTUM (0.73) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL1838394 | 0.79 | CYP19A1 (0.51) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL2628008 | 0.79 | CYP19A1 (0.52) | CYP19A1HDAC1NPC1RAB9AHSP90AB1 | |
| SCHEMBL846586 | 0.79 | CYP19A1 (0.52) | CYP19A1HDAC1HSP90AB1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CYP19A1 2116/4885HDAC1 1764/4885NPC1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.